RxDoctor Payments Data

Kathryn Millard

Psychiatric/Mental Health · North Collins, NYNPI 1033360102

Payments from drug & device makers

$1,730in general payments, 2019–2025

Across 63 payments — averaging $27.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$677
  • Teva Pharmaceuticals USA, Inc.$442
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$415
  • Biogen$100
  • Lundbeck LLC$29
  • Sunovion Pharmaceuticals Inc.$29
  • plus $38 from 2 others

What the payments were for

  • Food & beverage$1,71699%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,730 in reported general payments places this provider in the 75th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York

Medicare billing

Part B allowed, 2024
$5,513
Medicare patients
23
Services billed
69

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine12$97,900
Invega SustennaPaliperidone Palmitate24$68,625
VraylarCariprazine Hcl31$40,400
Lurasidone Hcl23$9,216
Aripiprazole75$4,711
Bupropion XlBupropion Hcl90$2,114
Quetiapine Fumarate66$2,107
Oxcarbazepine29$1,484
Duloxetine Hcl71$1,277
Trazodone Hcl112$1,121
Desvenlafaxine Succinate ErDesvenlafaxine Succinate24$990
Buspirone Hcl47$898
Lamotrigine45$815
Hydroxyzine Hcl32$813
Mirtazapine46$774

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$442$97,90012 claims
AbbVieVraylar$677$40,40031 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in North Collins

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →